PROPHYLAXIS AND TREATMENT OF SIDE EFFECTS OF ANTIANGIOGENIC THERAPY IN PATIENTS WITH METASTATIC COLORECTAL CARCINOMA


如何引用文章

全文:

详细

The review analyzed data from the literature and personal experience of the application of anti-angiogenic therapy in metastatic colorectal cancer. There are presented practical advices on prevention and treatment of the most common side effects of anti-angiogenic therapy.

作者简介

Andrey Meshcheryakov

N.N. Blokhin Russian Cancer Research Center

Email: a_meshcheryakov@mail.ru
MD, PhD, Senior Researcher of the Department of the Combined Chemotherapy and Treatment of Cancer of the Research Institute of Clinical Oncology; Moscow, 115478, Russian Federation. Moscow, 115478, Russian Federation

参考

  1. Van Cutsem E., Cervantes A., Adam R., Sobrero A., Van Krieken J.H., Aderka A. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 2016. doi: 10.1093/annonc/mdw235.
  2. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Naure. Med. 2003; 9(6): 669-76.
  3. Giantonio B.J., Catalano P.J., Meropol N.J., O’Dwyer P.J., Mitchel E.P., Alberts S.R. et al. Bevacizumab in combination with oxaliplatin, fluorouracil and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 2007; 25: 1530-44.
  4. Cartwright T.H. Adverse events associated with antiangiogenic agents in combination with cytotoxic chemotherapy in metastatic colorectal cancer and their management. Clin. Colorect. Cancer. 2013; 12(2): 86-94.
  5. Van Cutsem E., Tabernero J., Lakomy R., Prenen H., Prausova J., Macarulla T. et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 2012; 28: 3499-506.
  6. Eremina V., Jefferson J.A., Kowalewska J., Hochster H., Haas M., Weisstuch J. et al. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 2008; 358(11): 1129-36.
  7. Gressett S.M., Shah S.R. Intricacies of bevacizumab-induced toxicities and their management. Ann. Pharmacother. 2009; 43: 490-501.
  8. Antiangiogenic Therapy: Tolerability and Management of Side Effects. The Angiogenesis Foundation 2009 / Eds. M.E. Lacouture, D.J. Lenihan, S.E. Quaggin. http://www.angio.org/pdf/Angio_Poster_Final_6-30.pdf
  9. Maitland M.L., Bakris G.L., Black H.R., Chen H.X., Durand J.B., Elliott W.J. et al. Initial assessment, surveillance and management of blood pressure in patient receiving vascular endothelial growth factor signaling pathway inhibitors. J. Natl. Cancer Inst. 2010; 102(9): 596-604.
  10. Copur M.S., Obermiller A. An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition. Clin. Colorect. Cancer. 2011; 10(3): 151-6.
  11. Sundararajan S., Kumar A., Poongkunran M., Kannan A., Vogelzang N.J. Cardiovascular adverse effects of targeted antiangiogenic drugs: mechanisms and management. Future Oncol. 2016; 10.2217/fon.16.4
  12. Ghiringhelli F., Vincent J., Beltjens F., Bengrine L., Ladoire S. Fluorouracil, leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients. Invest. New Drugs. 2015; 33: 1263-6.

版权所有 © Eco-Vector, 2017


 


##common.cookie##